SBPH Spring Bank Pharmaceuticals, In

13.10
-0.23  -2%
Previous Close 13.33
Open 13.24
Price To book 11.42
Market Cap 123.35M
Shares 9,416,000
Volume 52,896
Short Ratio 4.69
Av. Daily Volume 20,586

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initial data released May 23, 2017. Second cohort enrolling with top-line results due 4Q 2017.
SB 9200
Hepatitis B (HBV)
Phase 2 to be initated pending funding.
SB 9200
Respiratory syncytial virus (RSV)

Latest News

  1. Spring Bank Pharmaceuticals Prices $37.5 Million Public Offering of Common Stock
  2. Spring Bank Pharmaceuticals Announces Proposed Public Offering of Common Stock
  3. Spring Bank Provides Update on its Next-Generation STING Platform and Announces Publication of an Abstract at ASCO Related to its Lead STING Agonist Candidate, SB 11285
  4. Spring Bank Pharmaceuticals Announces Top-Line Results from the Initial Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)
  5. Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial
  6. Spring Bank Pharmaceuticals Announces the Data Safety Monitoring Board Approves Dose Escalation of SB 9200 for the Second Cohort of the Phase 2a Segment of the ACHIEVE Trial, a Global Phase 2 Clinical Trial for Chronic Hepatitis B Virus (HBV)
  7. Spring Bank Pharmaceuticals to Present at the East Coast IDEAS Investor Conference on May 18th in Boston
  8. Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial and Operational Results
  9. ETFs with exposure to Spring Bank Pharmaceuticals, Inc. : April 21, 2017
  10. Spring Bank Pharmaceuticals, Inc. :SBPH-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  11. SBPH: 2016 Results Sustaining Continued HBV/STING Development
  12. Spring Bank Pharmaceuticals to Present at the 2nd Annual Disruptive Growth & Healthcare Conference in NYC on February 16
  13. Spring Bank Pharmaceuticals Inc (SBPH) An Ace Up Gilead Sciences, Inc. (GILD)’s Sleeve
  14. Spring Bank (SBPH) Inks 3rd Collaboration Agreement